Barclays
SPRO icon

Barclays’s Spero Therapeutics SPRO Stock Holding History

Barclays’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-204
Closed – – 5118
2022
Q2 		$0 Sell
204
-3,726
-95% -$10.8K ﹤0.01% 5246
2022
Q1 		$35K Sell
3,930
-25,441
-87% -$261K ﹤0.01% 4249
2021
Q4 		$470K Buy
29,371
+19,406
+195% +$308K ﹤0.01% 3234
2021
Q3 		$183K Buy
9,965
+4,401
+79% +$70.6K ﹤0.01% 3665
2021
Q2 		$77K Sell
5,564
-16,076
-74% -$225K ﹤0.01% 3947
2021
Q1 		$319K Buy
21,640
+14,940
+223% +$263K ﹤0.01% 3467
2020
Q4 		$130K Sell
6,700
-1,858
-22% -$29K ﹤0.01% 4008
2020
Q3 		$96K Sell
8,558
-1,151
-12% -$13.6K ﹤0.01% 4278
2020
Q2 		$130K Buy
9,709
+5,389
+125% +$60.5K ﹤0.01% 4355
2020
Q1 		$34K Sell
4,320
-7,041
-62% -$62.1K ﹤0.01% 5433
2019
Q4 		$109K Buy
11,361
+5,853
+106% +$63.1K ﹤0.01% 5439
2019
Q3 		$58K Sell
5,508
-1,281
-19% -$13.5K ﹤0.01% 5835
2019
Q2 		$78K Buy
6,789
+4,222
+164% +$50.8K ﹤0.01% 5863
2019
Q1 		$33K Buy
2,567
+2,131
+489% +$22.6K ﹤0.01% 6133
2018
Q4 		$2K Sell
436
-3,121
-88% -$25.3K ﹤0.01% 6738
2018
Q3 		$37K Buy
3,557
+3,069
+629% +$35.6K ﹤0.01% 6234
2018
Q2 		$7K Sell
488
-803
-62% -$10.3K ﹤0.01% 6645
2018
Q1 		$19K Buy
1,291
+335
+35% +$4.06K ﹤0.01% 6454
2017
Q4 		$11K Buy
+956
New +$11.7K ﹤0.01% 6496

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Barclays's SPRO Position: Q3 2022 in Review

Barclays sold out of Spero Therapeutics (SPRO) in Q3 2022, closing a stake of 204 shares.

Barclays first reported a position in SPRO in Q4 2017 and held it in 19 quarters. The position peaked at $470K in Q4 2021. 69 funds tracked by Wall St. Rank hold SPRO as of Q3 2022.

  • Barclays reported no remaining Spero Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Barclays sold 204 Spero Therapeutics shares in Q3 2022.
  • Barclays first reported a position in Spero Therapeutics in Q4 2017 and held it in 19 quarters.
  • Barclays's Spero Therapeutics position peaked at $470K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.